Research & Development

Pipeline

Scandion Oncology is building a pipeline of drugs that can revert cancer drug resistance through different mechanisms


Our Clinical Pipeline

Scandion Oncology has two programs in clinical development with our first-in-class lead compound SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of unresectable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Colorectal cancer
 
Pancreatic cancer
 

Our Pre-clinical Pipeline

Scandion Oncology is building a pre-clinical pipeline of drugs that can revert cancer drug resistance through different mechanisms, to increasingly broaden the offering of medicines able to combat various types of cancer drug resistance.

IMMUNO-ONCOLOGY
Multiple cancers
 
201
SCO-201
Solid tumors